Wnt signaling pathway analysis in renal cell carcinoma in young patients

Modern Pathology

Volumn 20, Issue 12, 2007, Pages 1217-1229

  Bruder, Elisabeth ^a   Moch, Holger ^b   Ehrlich, David ^c   Leuschner, Ivo ^d   Harms, Dieter ^d   Argani, Pedram ^e   Briner, Jakob ^f   Graf, Norbert ^g   Selle, Barbara ^h   Rufle, Alex ^a   Paulussen, Michael ⁱ   Koesters, Robert ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Institute for Histological and Cytological Diagnostics   (Switzerland)

^g SAARLAND UNIVERSITY   (Germany)

^h Annastift   (Germany)

ⁱ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Mutation analysis; Pediatric; Renal cell carcinoma; Wnt pathway

Indexed keywords

BETA CATENIN; PLAKOGLOBIN; WNT PROTEIN; WT1 PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME TRANSLOCATION; CHROMOSOME XP; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; CTNNG1 GENE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; NEPHROBLASTOMA; NEUROBLASTOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WT1 GENE;

EID: 36248944140     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800957     Document Type: Article

References (35)

1. Robbins PF, El-Gamil M, Li YF, et al. A mutated betacatenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-1192.
2. Zurawel RH, Chiappa SA, Allen C, et al. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998;58:896-899.
3. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-8851.
4. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998;58:2520-2523.
5. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-480.
6. Yasumoto K, Takeda K, Saito H, et al. Microphthalmiaassociated transcription factor interacts with LEF-1, a mediator of Wnt signaling. EMBO J 2002;21:2703-2714.
7. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001;159:179-192.
8. Bruder E, Passera O, Harms D, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004;28:1117-1132.
9. Selle B, Furtwaengler R, Graf N, et al. Population-based study of renal cell carcinoma in children in Germany, 1980-2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer 2006;107:2906-2914.
10. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003;27:750-761.
11. Eble JN, Sauter G, Epstein JI, et al (eds). Tumours of the Kidney. In: WHO Classification of Tumours: Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon, France, 2004, pp 12-43.
12. Arroyo MR, Green DM, Perlman EJ, et al. The spectrum of metanephric adenofibroma and related lesions: clinicopathologic study of 25 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol 2001;25:433-444.
13. Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-3882.
14. Maiti S, Alam R, Amos CI, et al. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 2000;60:6288-6292.
15. Sansom OJ, Griffiths DF, Reed KR, et al. Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene 2005;24:8205-8210.
16. Argani P, Olgac S, Tickoo S, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007;31:1149-1160.
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
18. Kim Y-S, Kang YK, Kim JB, et al. Catenin expression and mutational analysis in renal cell carcinomas. Pathol Internat 2000;50:725-730.
19. Koesters R, von Knebel Doeberitz M. The Wnt signaling pathway in solid childhood tumors. Cancer Lett 2003;198:123-138.
20. Li CM, Kim CE, Margolin AA, et al. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004;165:1943-1953.
21. National Center for Biotechnology Information (NCBI). Single Nucleotide Polymorphism. rs2293302. Build 13. Revision May 2006 (online). Available at: http:// www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2293302; Accessed 13 June 2007.
22. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-3305.
23. Barth AI, Näthke IS, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 1997;9:683-690.
24. Kolligs FT, Kolligs B, Hajra KM, et al. Gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 2000;14:1319-1331.
25. Caca K, Kolligs FT, Ji X, et al. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 1999;10:369-376.
26. Koesters R, Adams V, Hassam S. Mutational analysis of the tumor suppressor gene WT1: detection of a novel homozygous point mutation in sporadic unilateral Wilms tumor. Int J Oncol 1995;7:1103-1107.
27. Varanasi R, Bardeesy N, Ghahremani M, et al. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci USA 1994;91:3554-3558.
28. Steingrimsson E, Copeland NG, Jenkins NA. Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 2004;38:365-411.
29. Hemesath TJ, Steingrimsson E, McGill G, et al. microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 1994;8:2770-2780.
30. Steingrimsson E, Tessarollo L, Pathak B, et al. Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. Proc Natl Acad Sci USA 2002;99:4477-4482.
31. Davis IJ, Kim JJ, Ozsolak F, et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 2006;9:473-484.
32. Takeda K, Yasumoto K, Takada R, et al. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J Biol Chem 2000;275:14013-14016.
33. Widlund HR, Horstmann MA, Price ER, et al. Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 2002;158:1079-1087.
34. Peruzzi B, Gagani A, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic β-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci 2006;103:14531-14536.
35. Coppes MJ, Campbell CE, Williams BR. The role of WT1 in Wilms tumorigenesis. FASEB 1993;7:886-895.